| Literature DB >> 34863147 |
Yifan Chen1, Hongzhi Liu1, Jinyu Zhang1, Yijun Wu1, Weiping Zhou2, Zhangjun Cheng3, Jianying Lou4, Shuguo Zheng5, Xinyu Bi6, Jianming Wang7, Wei Guo8, Fuyu Li9, Jian Wang10, Yamin Zheng11, Jingdong Li12, Shi Cheng13, Yongyi Zeng14,15, Jingfeng Liu16.
Abstract
BACKGROUND: At present, hepatectomy is still the most common and effective treatment method for intrahepatic cholangiocarcinoma (ICC) patients. However, the postoperative prognosis is poor. Therefore, the prognostic factors for these patients require further exploration. Whether microvascular invasion (MVI) plays a crucial role in the prognosis of ICC patients is still unclear. Moreover, few studies have focused on preoperative predictions of MVI in ICC patients.Entities:
Keywords: Intrahepatic cholangiocarcinoma; Microvascular invasion; Prediction model; Prognosis
Mesh:
Year: 2021 PMID: 34863147 PMCID: PMC8645153 DOI: 10.1186/s12885-021-09035-5
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1The flow chart of selected patients. ICC, Intrahepatic cholangiocarcinoma
Comparison of clinicopathological characteristics between MVI-positive and negative group before PSM
| Variables | MVI-negative group | MVI-positive group | Total | |
|---|---|---|---|---|
| ( | ( | ( | ||
| < 60 | 369 (59.2%) | 55 (67.9%) | 0.168 | 424 (60.2%) |
| ≥ 60 | 254 (40.8%) | 26 (32.1%) | 280 (39.8%) | |
| Male | 365 (58.6%) | 43 (53.1%) | 0.410 | 408 (58.0%) |
| Female | 258 (41.4%) | 38 (46.9%) | 296 (42.0%) | |
| No | 397 (63.7%) | 54 (66.7%) | 0.692 | 451 (64.1%) |
| Yes | 226 (36.3%) | 27 (33.3%) | 253 (35.9%) | |
| Stage A | 455 (73.0%) | 69 (85.2%) | 0.026 | 524 (74.4%) |
| Stage B | 168 (27.0%) | 12 (14.8%) | 180 (25.6%) | |
| ≤ 20 | 389 (62.4%) | 49 (60.5%) | 0.827 | 438 (62.2%) |
| > 20 | 234 (37.6%) | 32 (39.5%) | 266 (37.8%) | |
| < 200 | 493 (79.1%) | 60 (74.1%) | 0.368 | 553 (78.6%) |
| ≥ 200 | 130 (20.9%) | 21 (25.9%) | 151 (21.4%) | |
| < 5 | 488 (78.3%) | 52 (64.2%) | 0.007 | 540 (76.7%) |
| ≥ 5 | 135 (21.7%) | 29 (35.8%) | 164 (23.3%) | |
| ≥ 800 | 517 (83.0%) | 57 (70.4%) | 0.009 | 574 (81.5%) |
| < 800 | 106 (17.0%) | 24 (29.6%) | 130 (18.5%) | |
| No | 527 (84.6%) | 69 (85.2%) | 1.000 | 596 (84.7%) |
| Yes | 96 (15.4%) | 12 (14.8%) | 108 (15.3%) | |
| Yes | 30 (4.8%) | 5 (6.2%) | 0.797 | 35 (5.0%) |
| No | 593 (95.2%) | 76 (93.8%) | 669 (95.0%) | |
| No | 426 (68.4%) | 43 (53.1%) | 0.009 | 469 (66.6%) |
| Yes | 197 (31.6%) | 38 (46.9%) | 235 (33.4%) | |
| No | 280 (44.9%) | 24 (29.6%) | 0.013 | 304 (43.2%) |
| Yes | 343 (55.1%) | 57 (70.4%) | 400 (56.8%) | |
| ≤ 5 | 245 (39.3%) | 22 (27.2%) | 0.045 | 267 (37.9%) |
| > 5 | 378 (60.7%) | 59 (72.8%) | 437 (62.1%) | |
| Single | 455 (73.0%) | 50 (61.7%) | 0.046 | 505 (71.7%) |
| Multiple | 168 (27.0%) | 31 (38.3%) | 199 (28.3%) | |
| No | 465 (74.6%) | 48 (59.3%) | 0.005 | 513 (72.9%) |
| Yes | 158 (25.4%) | 33 (40.7%) | 191 (27.1%) | |
| < 1 | 432 (69.3%) | 52 (64.2%) | 0.417 | 484 (68.8%) |
| ≥ 1 | 191 (30.7%) | 29 (35.8%) | 220 (31.2%) | |
| Moderate or high | 510 (81.9%) | 54 (66.7%) | 0.002 | 564 (80.1%) |
| Poor | 113 (18.1%) | 27 (33.3%) | 140 (19.9%) | |
| No | 533 (85.6%) | 57 (70.4%) | < 0.001 | 590 (83.8%) |
| Yes | 90 (14.4%) | 24 (29.6%) | 114 (16.2%) | |
| No | 602 (96.6%) | 77 (95.1%) | 0.691 | 679 (96.4%) |
| Yes | 21 (3.4%) | 4 (4.9%) | 25 (3.6%) | |
| < 15 | 366 (58.7%) | 34 (42.0%) | 0.006 | 400 (56.8%) |
| ≥ 15 | 257 (41.3%) | 47 (58.0%) | 304 (43.2%) | |
Abbreviations: MVI Microvascular invasion, PSM Propensity Score Matching, CA199 Carbohydrate antigen 199, CEA Carcinoembryonic antigen
Comparison of clinicopathological characteristics between MVI-positive and negative group after PSM
| Variables | MVI-negative group | MVI-positive group | Total | |
|---|---|---|---|---|
| ( | ( | ( | ||
| < 60 | 102 (67.5%) | 52 (66.7%) | 1.000 | 154 (67.2%) |
| ≥ 60 | 49 (32.5%) | 26 (33.3%) | 75 (32.8%) | |
| Male | 86 (57.0%) | 42 (53.8%) | 0.758 | 128 (55.9%) |
| Female | 65 (43.0%) | 36 (46.2%) | 101 (44.1%) | |
| No | 94 (62.3%) | 51 (65.4%) | 0.748 | 145 (63.3%) |
| Yes | 57 (37.7%) | 27 (34.6%) | 84 (36.7%) | |
| Stage A | 132 (87.4%) | 66 (84.6%) | 0.701 | 198 (86.5%) |
| Stage B | 19 (12.6%) | 12 (15.4%) | 31 (13.5%) | |
| ≤ 20 | 95 (62.9%) | 48 (61.5%) | 0.952 | 143 (62.4%) |
| > 20 | 56 (37.1%) | 30 (38.5%) | 86 (37.6%) | |
| < 200 | 111 (73.5%) | 58 (74.4%) | 1.000 | 169 (73.8%) |
| ≥200 | 40 (26.5%) | 20 (25.6%) | 60 (26.2%) | |
| < 5 | 100 (66.2%) | 51 (65.4%) | 1.000 | 151 (65.9%) |
| ≥ 5 | 51 (33.8%) | 27 (34.6%) | 78 (34.1%) | |
| ≥ 800 | 118 (78.1%) | 56 (71.8%) | 0.367 | 174 (76.0%) |
| < 800 | 33 (21.9%) | 22 (28.2%) | 55 (24.0%) | |
| No | 527 (84.6%) | 69 (85.2%) | 1.000 | 596 (84.7%) |
| Yes | 96 (15.4%) | 12 (14.8%) | 108 (15.3%) | |
| Yes | 142 (94.0%) | 73 (93.6%) | 1.000 | 215 (93.9%) |
| No | 9 (6.0%) | 5 (6.4%) | 14 (6.1%) | |
| No | 80 (53.0%) | 43 (55.1%) | 0.866 | 123 (53.7%) |
| Yes | 71 (47.0%) | 35 (44.9%) | 106 (46.3%) | |
| No | 48 (31.8%) | 24 (30.8%) | 0.994 | 72 (31.4%) |
| Yes | 103 (68.2%) | 54 (69.2%) | 157 (68.6%) | |
| ≤ 5 | 43 (28.5%) | 22 (28.2%) | 1.000 | 65 (28.4%) |
| > 5 | 108 (71.5%) | 56 (71.8%) | 164 (71.6%) | |
| Single | 88 (58.3%) | 47 (60.3%) | 0.883 | 135 (59.0%) |
| Multiple | 63 (41.7%) | 31 (39.7%) | 94 (41.0%) | |
| No | 89 (58.9%) | 46 (59.0%) | 1.000 | 135 (59.0%) |
| Yes | 62 (41.1%) | 32 (41.0%) | 94 (41.0%) | |
| < 1 | 107 (70.9%) | 51 (65.4%) | 0.485 | 158 (69.0%) |
| ≥ 1 | 44 (29.1%) | 27 (34.6%) | 71 (31.0%) | |
| Moderate or high | 108 (71.5%) | 54 (69.2%) | 0.835 | 162 (70.7%) |
| Poor | 43 (28.5%) | 24 (30.8%) | 67 (29.3%) | |
| No | 111 (73.5%) | 57 (73.1%) | 1.000 | 168 (73.4%) |
| Yes | 40 (26.5%) | 21 (26.9%) | 61 (26.6%) | |
| No | 142 (94.0%) | 74 (94.9%) | 1.000 | 216 (94.3%) |
| Yes | 9 (6.0%) | 4 (5.1%) | 13 (5.7%) | |
| < 15 | 63 (41.7%) | 34 (43.6%) | 0.897 | 97 (42.4%) |
| ≥ 15 | 88 (58.3%) | 44 (56.4%) | 132 (57.6%) | |
Abbreviations: MVI Microvascular invasion, PSM Propensity Score Matching, CA199 Carbohydrate antigen 199, CEA Carcinoembryonic antigen
Univariate and multivariate Cox regression for overall survival in ICC patients after curative resection before PSM
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| 1.114 | 0.900–1.379 | 0.319 | ||||
| 1.065 | 0.861–1.317 | 0.563 | ||||
| 0.926 | 0.742–1.156 | 0.498 | ||||
Grade A vs Grade B | 1.404 | 1.122–1.757 | 0.003 | 1.394 | 1.098–1.769 | 0.006 |
< 20 vs ≥20 | 1.346 | 1.089–1.663 | 0.006 | 1.320 | 1.057–1.648 | 0.014 |
< 200 vs ≥200 | 1.066 | 0.822–1.383 | 0.630 | |||
| 1.302 | 1.020–1.660 | 0.034 | 1.364 | 1.060–1.754 | 0.016 | |
< 800 vs ≥800 | 1.162 | 0.890–1.518 | 0.270 | |||
no vs yes | 1.035 | 0.771–1.390 | 0.820 | |||
≤5 vs > 5 | 1.730 | 1.377–2.174 | < 0.001 | 1.560 | 1.236–1.968 | < 0.001 |
single vs multiple | 1.614 | 1.289–2.020 | < 0.001 | |||
| 0.745 | 0.588–0.945 | 0.015 | 0.777 | 0.608–0.992 | 0.043 | |
no vs yes | 1.689 | 1.350–2.112 | < 0.001 | 1.487 | 1.175–1.882 | 0.001 |
no vs yes | 1.074 | 0.639–1.806 | 0.786 | |||
moderate or high vs poor | 0.957 | 0.731–1.254 | 0.751 | |||
no vs yes | 1.734 | 1.387–2.169 | < 0.001 | |||
| 1.325 | 0.776–2.264 | 0.303 | ||||
| 1.636 | 1.215–2.203 | 0.001 | 1.399 | 1.022–1.916 | 0.036 | |
| 1.111 | 0.898–1.374 | 0.335 | ||||
Abbreviations: ICC Intrahepatic cholangiocarcinoma, PSM Propensity Score Matching, HR Hazard ratio, CI Confidence interval, CA199 Carbohydrate antigen 199, CEA Carcinoembryonic antigen, MVI Microvascular invasion
Univariate and multivariate Cox regression for recurrence-free survival in ICC patients after curative resection before PSM
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| 0.879 | 0.713–1.083 | 0.227 | ||||
| 1.098 | 0.895–1.347 | 0.369 | ||||
| 0.946 | 0.764–1.171 | 0.610 | ||||
Grade A vs Grade B | 1.655 | 1.335–2.052 | < 0.001 | 1.539 | 1.221–1.939 | < 0.001 |
< 20 vs ≥20 | 1.523 | 1.242–1.867 | < 0.001 | 1.332 | 1.074–1.651 | 0.009 |
< 200 vs ≥200 | 0.798 | 0.614–1.036 | 0.090 | |||
| 0.983 | 0.768–1.257 | 0.889 | ||||
< 800 vs ≥800 | 1.065 | 0.821–1.382 | 0.634 | |||
no vs yes | 0.838 | 0.622–1.129 | 0.246 | |||
≤5 vs > 5 | 1.481 | 1.194–1.836 | < 0.001 | |||
single vs multiple | 1.440 | 1.155–1.796 | 0.001 | |||
| 0.851 | 0.682–1.062 | 0.154 | ||||
no vs yes | 1.686 | 1.357–2.094 | < 0.001 | 1.511 | 1.206–1.893 | < 0.001 |
no vs yes | 0.674 | 0.388–1.173 | 0.163 | |||
moderate or high vs poor | 0.785 | 0.599–1.029 | 0.080 | |||
no vs yes | 1.815 | 1.465–2.249 | < 0.001 | 1.535 | 1.231–1.915 | < 0.001 |
| 0.990 | 0.569–1.722 | 0.971 | ||||
| 1.840 | 1.392–2.431 | < 0.001 | 1.742 | 1.303–2.329 | < 0.001 | |
| 1.043 | 0.849–1.281 | 0.688 | ||||
Abbreviations: ICC Intrahepatic cholangiocarcinoma, PSM Propensity Score Matching, HR Hazard ratio, CI Confidence interval, CA199 Carbohydrate antigen 199, CEA Carcinoembryonic antigen, MVI Microvascular invasion
Univariate and multivariate Cox regression for overall survival in ICC patients after curative resection after PSM
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| 1.218 | 0.841–1.764 | 0.297 | ||||
| 1.006 | 0.703–1.440 | 0.973 | ||||
| 0.879 | 0.602–1.283 | 0.505 | ||||
Grade A vs Grade B | 2.187 | 1.407–3.399 | 0.001 | 2.098 | 1.344–3.274 | 0.001 |
< 20 vs ≥20 | 1.325 | 0.927–1.895 | 0.123 | |||
< 200 vs ≥200 | 0.814 | 0.53–1.249 | 0.346 | |||
| 1.431 | 0.991–2.066 | 0.056 | ||||
< 800 vs ≥800 | 1.000 | 0.667–1.498 | 0.999 | |||
no vs yes | 0.798 | 0.477–1.333 | 0.388 | |||
≤5 vs > 5 | 1.529 | 1.006–2.323 | 0.047 | |||
single vs multiple | 1.215 | 0.848–1.740 | 0.289 | |||
| 0.940 | 0.632–1.397 | 0.759 | ||||
no vs yes | 1.212 | 0.847–1.734 | 0.293 | |||
no vs yes | 0.978 | 0.455–2.100 | 0.954 | |||
moderate or high vs poor | 0.868 | 0.577–1.306 | 0.498 | |||
no vs yes | 1.526 | 1.014–2.297 | 0.043 | 1.423 | 0.941–2.15 | 0.094 |
| 1.213 | 0.592–2.486 | 0.598 | ||||
| 1.542 | 1.073–2.217 | 0.019 | 1.576 | 1.096–2.266 | 0.014 | |
| 0.894 | 0.624–1.282 | 0.542 | ||||
Abbreviations: ICC Intrahepatic cholangiocarcinoma, PSM Propensity Score Matching, HR Hazard ratio, CI Confidence interval, CA199 Carbohydrate antigen 199, CEA Carcinoembryonic antigen, MVI Microvascular invasion
Univariate and multivariate Cox regression for recurrence-free survival in ICC patients after curative resection after PSM
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| 1.047 | 0.723–1.517 | 0.807 | ||||
| 1.192 | 0.840–1.692 | 0.326 | ||||
| 0.899 | 0.620–1.302 | 0.572 | ||||
Grade A vs Grade B | 2.004 | 1.273–3.153 | 0.003 | 1.601 | 0.991–2.586 | 0.055 |
< 20 vs ≥20 | 1.489 | 1.049–2.113 | 0.026 | 1.321 | 0.915–1.907 | 0.137 |
< 200 vs ≥200 | 0.795 | 0.525–1.204 | 0.279 | |||
| 1.031 | 0.710–1.498 | 0.871 | ||||
< 800 vs ≥800 | 1.086 | 0.730–1.617 | 0.683 | |||
no vs yes | 0.771 | 0.462–1.286 | 0.319 | |||
≤5 vs > 5 | 1.650 | 1.089–2.501 | 0.018 | |||
single vs multiple | 1.262 | 0.885–1.798 | 0.198 | |||
| 0.964 | 0.657–1.415 | 0.853 | ||||
no vs yes | 1.357 | 0.954–1.930 | 0.090 | |||
no vs yes | 0.742 | 0.327–1.686 | 0.476 | |||
moderate or high vs poor | 0.619 | 0.407–0.942 | 0.025 | 0.727 | 0.474–1.116 | 0.145 |
no vs yes | 2.327 | 1.510–3.585 | < 0.001 | 2.147 | 1.386–3.326 | 0.001 |
| 0.950 | 0.443–2.036 | 0.894 | ||||
| 2.038 | 1.433–2.898 | < 0.001 | 2.057 | 1.445–2.929 | < 0.001 | |
| 1.022 | 0.715–1.460 | 0.905 | ||||
Abbreviations: ICC Intrahepatic cholangiocarcinoma, PSM Propensity Score Matching, HR Hazard ratio, CI Confidence interval, CA199 Carbohydrate antigen 199, CEA Carcinoembryonic antigen, MVI Microvascular invasion
Fig. 2Comparison of survival rate between MVI-positive and negative groups before PSM. A Overall Survival; B Recurrence-Free Survival. MVI, microvascular invasion. PSM, Propensity Score Matching
Fig. 3Comparison of survival rate between MVI-positive and negative groups after PSM. A Overall Survival; B Recurrence-Free Survival. MVI, microvascular invasion. PSM, Propensity Score Matching
Fig. 4The flow chart of selected patients for constructing prediction model
Univariate and multivariate logistic regression for the occurrence of MVI in ICC patients
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| 0.963 | 0.928–0.998 | 0.039 | 0.962 | 0.926–1.000 | 0.049 | |
| 1.054 | 0.478–2.321 | 0.897 | ||||
| 0.676 | 0.312–1.463 | 0.320 | ||||
| 1.112 | 0.929–1.331 | 0.246 | ||||
| 1.298 | 0.630–2.675 | 0.480 | ||||
| 0.997 | 0.973–1.021 | 0.791 | ||||
| 0.969 | 0.900–1.043 | 0.395 | ||||
| 0.945 | 0.850–1.052 | 0.301 | ||||
| 1.244 | 0.958–1.615 | 0.101 | ||||
| 1.003 | 0.997–1.009 | 0.391 | ||||
| 1.035 | 0.881–1.217 | 0.676 | ||||
| 1.004 | 1.002–1.007 | 0.001 | 1.005 | 1.002–1.007 | 0.001 | |
| 1.002 | 1.000–1.003 | 0.075 | ||||
| 1.001 | 0.999–1.002 | 0.332 | ||||
| 1.008 | 0.996–1.020 | 0.189 | ||||
| 1.434 | 0.643–3.200 | 0.379 | ||||
single vs multiple | 3.318 | 1.495–7.363 | 0.003 | 3.491 | 1.496–8.148 | 0.004 |
Abbreviations: MVI Microvascular invasion, ICC Intrahepatic cholangiocarcinoma, OR Odds ratio, CI Confidence interval, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, LMR Lymphocyte-to-monocyte ratio, GGT Gamma-glutamyl transpeptidase, AFP Alpha-fetoprotein, CA199 Carbohydrate antigen 199, CEA Carcinoembryonic antigen
Fig. 5The nomogram of preoperative prediction model for occurrence of MVI. GGT, gamma-glutamyl transpeptidase. TN, preoperative image tumor number. MVI, microvascular invasion
Fig. 6The calibration curve for the nomogram